Polymers having halogen-containing sites and pharmaceutical compositions using the polymer

By introducing haloalkyl structures into polymer segments to form stable complexes, the challenges of drug delivery in DDS technology are solved, achieving efficient targeted delivery and controlled release, and improving the uptake efficiency of drugs in target cells.

CN117321117BActive Publication Date: 2026-11-17AGC INC +2
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202280020215.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-03-10
Filing Date
2022-03-07
Publication Date
2026-11-17
Estimated Expiration
2042-03-07

AI Technical Summary

Technical Problem

Existing DDS technology struggles to effectively concentrate drugs to the lesion site, control drug release, and improve uptake efficiency to target cells, especially when crossing mucous membranes such as the skin and intestines and the blood-brain barrier.

Method used

By employing polymer segments with specific structures having halogenated alkyl groups in the side chain portion, combined with hydrophilic polymer segments and/or polycationic segments, a more stable complex is formed, thereby improving the efficiency and selectivity of drug delivery.

Benefits of technology

It achieves highly efficient targeted drug delivery, improves drug uptake efficiency in target cells, controls drug release, and enhances the ability to cross mucosa and blood-brain barrier.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117321117B_ABST
    Figure CN117321117B_ABST
Patent Text Reader

Abstract

This invention provides polymers represented by the following formula (I), etc., which are useful as drug carriers for effectively delivering drugs to target sites. (In the formula, each symbol is as described in the specification.)
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to polymers useful as carriers for effectively delivering drugs to target sites. Background Technology

[0002] Drugs that require effective action at the target site, such as nucleic acid pharmaceuticals, are highly anticipated for application in treating various diseases currently considered difficult to treat, including cancer and hereditary diseases, because they can control various genes within cells. On the other hand, due to the low stability of nucleic acid molecules within organisms, appropriate delivery technologies (DDS) are needed to deliver nucleic acid pharmaceuticals to target cells.

[0003] For example, as a nucleic acid delivery technology, the following technique has been disclosed: utilizing a block copolymer having hydrophilic polymer segments and cationic polymer segments, and forming a complex (polyionic complex) between the nucleic acid and the block copolymer by means of electrostatic interaction (Patent Documents 1-2). While these patent documents describe an excellent nucleic acid pharmaceutical delivery technology, they do not describe block copolymers containing polymer segments with a specific structure in which one or more alkyl groups (also referred to as "halogenated alkyl groups") have substituted halogen atoms in their side chains.

[0004] As related to DDS technology, non-patent documents 1 to 3 describe block copolymers having haloalkyl groups, but neither are there any descriptions or teachings regarding polymers of the present invention having the specific structures shown in formulas (I) to (IV) described later.

[0005] Existing technical documents

[0006] Patent documents

[0007] Patent Document 1: International Publication No. 2012 / 096399

[0008] Patent Document 2: International Publication No. 2017 / 086467

[0009] Non-patent literature

[0010] Non-patent literature 1: Angew. Chem. Int. Ed. 2016, 55, 755-759

[0011] Non-patent literature 2: Macromol. Biosci. 2017, 17, 1700114

[0012] Non-patent literature 3: Mater. Chem. B, 2018, 6, 7230-7238 Summary of the Invention

[0013] The problem the invention aims to solve

[0014] Drug delivery system (DDS) technology, which aims to deliver drugs effectively to target organs (target sites), requires the following three functions: 1) the ability to concentrate the drug delivery to the lesion site; 2) the ability to appropriately control the release of the drug from the formulation; and 3) the ability to improve the uptake efficiency to target cells by enhancing the absorption of the drug through mucous membranes such as the skin and intestines, and the permeability of the blood-brain barrier. However, in previous DDS technologies, these functional improvements have not always been satisfactory. The purpose of this invention is to solve the problems in this field of DDS technology.

[0015] Solution for solving the problem

[0016] The inventors conducted in-depth research and conceived of polymer segments with specific structures containing haloalkyl groups in their side chains. They discovered that by forming polymers using these segments alone or in combination with hydrophilic polymer segments and / or polycationic segments, the aforementioned problems could be solved. Furthermore, they also found that drugs containing haloalkyl groups can form more stable complexes with these polymers, thus completing this invention. Specifically, the present invention is as follows.

[0017] [1] A polymer represented by the following formula (I), (II), (III) or (IV).

[0018]

[0019] [In each formula, R] 1 and R 2 Each can independently represent a hydrogen atom or an optional substituted C atom. 1-12 alkyl,

[0020] R 3 Represents the side chain of any amino acid.

[0021] A represents a single bond or a hydrophilic polymer chain.

[0022] L 1a and L 1b Each can independently represent a single bond or a linking group.

[0023] L 2 Indicates a single bond or L 3 ,

[0024] L 3 The connector shown in expression (V) or (VI),

[0025]

[0026] (In the formula, m and n each independently represent integers from 0 to 5,

[0027] The asterisk (*) on the left indicates the bonding position with the -NH- group, and

[0028] The asterisk (*) on the right indicates the bonding position with the carbonyl group.

[0029] B represents C 1-20 Halogenated alkyl groups,

[0030] D represents a group containing a cation, a group containing an anion, or a group represented by formula (VII).

[0031] (In the formula, t represents an integer from 0 to 5,

[0032] ** indicates the bonding position with the -(CH2)q- group, and

[0033] G represents O or NH.

[0034] E represents NHCOR group, NHCOOR group, CONHR group, or COOR group.

[0035] R represents an alkyl group having 3 to 20 carbon atoms or a lipid-derived group.

[0036] z represents an integer from 2 to 500.

[0037] x represents the integers greater than 40% of z.

[0038] y represents an integer, which can be arbitrarily set to 0.

[0039] w represents an integer, which can be arbitrarily set to 0.

[0040] zxyw represents an integer, which can be arbitrarily set to 0.

[0041] zx represents an integer, which can be arbitrarily set to 0.

[0042] p, q, and r each independently represent integers from 1 to 10.

[0043] s represents an integer from 0 to 10.

[0044] (Whereinafter, in equations (III) and (IV), (i)A represents a single bond, and (ii)m represents an integer from 0 to 2.)

[0045] [2] According to the polymer described in [1] above, wherein in formula (I) or (II), the sum of x, y and w is more than 95% of z.

[0046] [3] According to the polymer described in [1] or [2] above, wherein A is a hydrophilic polymer chain.

[0047] [4] According to the polymer described in [1] or [2] above, wherein A is a single bond.

[0048] [5] The polymer according to any one of [1] to [4] above, wherein B is C 1-20 Fluoroalkyl groups.

[0049] [6] According to the polymer described in [5] above, wherein B is C in which all hydrogen atoms are replaced by fluorine atoms. 1-20 alkyl.

[0050] [7] A polymer-drug complex, which is formed by combining the polymer described in any one of [1] to [6] above with a drug.

[0051] [8] According to the polymer-drug complex described above [7], wherein the drug is a biopolymer.

[0052] [9] A pharmaceutical product containing, as an active ingredient, any one of [7] or [8].

[0053] The effects of the invention

[0054] The present invention provides a useful polymer for delivering drugs to target sites efficiently. Attached Figure Description

[0055] Figure 1 The evaluation results of using ASO as a nucleic acid in animal experiments on blood retention, as described later, are shown.

[0056] Figure 2 The evaluation results of using HDO as a nucleic acid in animal experiments on blood retention, as described later, are shown.

[0057] Figure 3 The evaluation results of using haloalkyl-modified HDO as a nucleic acid in animal experiments on blood retention, as described later, are shown. Detailed Implementation

[0058] The present invention will now be described in detail with reference to the embodiments.

[0059] Unless otherwise specified herein, all technical and scientific terms used in this specification shall have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Any methods and materials identical or equivalent to those described herein may be used in the implementation or testing of this invention; preferred methods and materials are described below. All publications and patents mentioned herein, for example for the purpose of describing and disclosing constructs and methodologies described in publications applicable in connection with the described invention, are incorporated herein by reference in their entirety.

[0060] The polymers used in this invention, when obtained as polymerization reactants, can exhibit a certain degree of polydispersity. Therefore, in this specification, when referring to polymer properties (molecular weight, degree of polymerization, charge, etc.), unless otherwise specified, the descriptions are based on the average of the polymer reactants exhibiting polydispersity as a whole.

[0061] In this specification, in the polymers represented by formulas (I) to (IV), structurally corresponding groups and parts are defined using the same symbols such as R1, A, B, x, y, z, etc., and these groups and parts are independent of each other in each polymer (I) to (IV). Therefore, for example, in preferred embodiments where groups and parts represented by the same symbols are used, the individual polymers (e.g., between polymers (I) and (II)) may be the same or different.

[0062] I. Regarding the polymers represented by formulas (I) to (IV) of the present invention

[0063] The present invention provides polymers represented by formulas (I), (II), (III) or (IV) below (in this specification, they are sometimes collectively referred to as "polymers of the present invention").

[0064]

[0065] [In each formula, R] 1 and R 2 Each can independently represent a hydrogen atom or an optional substituted C atom. 1-12 alkyl,

[0066] R 3 Represents the side chain of any amino acid.

[0067] A represents a single bond or a hydrophilic polymer chain.

[0068] L 1a and L 1b Each can independently represent a single bond or a linking group.

[0069] L 2 Indicates a single bond or L 3 ,

[0070] L 3 The connector shown in expression (V) or (VI),

[0071]

[0072] (In the formula, m and n each independently represent integers from 0 to 5,

[0073] The asterisk (*) on the left indicates the bonding position with the -NH- group, and

[0074] The asterisk (*) on the right indicates the bonding position with the carbonyl group.

[0075] B represents C 1-20 Halogenated alkyl groups,

[0076] D represents a group containing a cation, a group containing an anion, or a group represented by formula (VII).

[0077] (In the formula, t represents an integer from 0 to 5,

[0078] ** indicates the bonding position with the -(CH2)q- group, and

[0079] G represents O or NH.

[0080] E represents NHCOR group, NHCOOR group, CONHR group, or COOR group.

[0081] R represents an alkyl group having 3 to 20 carbon atoms or a lipid-derived group.

[0082] z represents an integer from 2 to 500.

[0083] x represents the integers greater than 40% of z.

[0084] y represents an integer, which can be arbitrarily set to 0.

[0085] w represents an integer, which can be arbitrarily set to 0.

[0086] zxyw represents an integer, which can be arbitrarily set to 0.

[0087] zx represents an integer, which can be arbitrarily set to 0.

[0088] p, q, and r each independently represent integers from 1 to 10.

[0089] s represents an integer from 0 to 10.

[0090] (Whereinafter, in equations (III) and (IV), (i)A represents a single bond, and (ii)m represents an integer from 0 to 2.)

[0091] In the above formulas, some structures [···] Z The portion shown represents a polymer containing segments with haloalkyl groups as side chains, a structural feature of the polymers of this invention (hereinafter sometimes referred to as "haloalkylated segments"). These "haloalkylated segments" are formed from one or more structural units, and can be polymers formed from one structural unit or copolymers formed from two or more structural units. In these copolymers, the polymerization order of the structural units constituting the copolymer is not particularly limited and is arbitrary; random copolymers and block copolymers are also possible.

[0092] In the polymers of the present invention shown in formulas (I) to (IV) above, the structural units are represented by the following partial structural formulas.

[0093] Polymer (peptide structure) of formula (I)

[0094]

[0095] Polymer (peptide structure) of formula (II)

[0096]

[0097] Polymer of formula (III) (polyethylene imine structure)

[0098]

[0099] Polymer of formula (IV) (polyethylene imine structure)

[0100]

[0101] In the polymers of the present invention, the structural units shown in the above-mentioned partial structural formulas (Ia), (II-a), (III-a) and (IV-a) are essential.

[0102] In this specification, the structural units shown in the above partial structural formulas are sometimes referred to as "monomer" or "monomer (Ia)".

[0103] The definitions of each symbol in equations (I) to (IV) are described in detail below.

[0104] (1) Polymer moieties containing haloalkylated segments

[0105] z represents the total number of monomers of each polymer shown in formulas (I) to (IV), each representing an integer from 2 to 500 independently.

[0106] x represents the total number of "haloalkylated segments", monomer (Ia), monomer (II-a), monomer (III-a) and monomer (IV-a) in each polymer represented by formulas (I) to (IV), and each independently represents an integer greater than 40% of z.

[0107] For both monomer (Ia) and monomer (II-a), x is preferably an integer that is more than 50% of z, each independently.

[0108] y represents the total number of monomers (Ib) and (II-b) in each polymer shown in equations (I) and (II), each of which is an independent integer and is optionally 0. y can be, for example, an integer greater than or equal to 1, an integer greater than or equal to 2, or an integer greater than or equal to 5. In addition, y can be, for example, an integer less than or equal to 200, an integer less than or equal to 100, an integer less than or equal to 80, an integer less than or equal to 40, or an integer less than or equal to 20.

[0109] w represents the total number of monomers (Ic) and (II-c) in each polymer shown in equations (I) and (II), each of which is an independent integer and is optionally 0. w can be, for example, an integer greater than or equal to 1, an integer greater than or equal to 2, or an integer greater than or equal to 5. In addition, w can be, for example, an integer less than or equal to 200, an integer less than or equal to 100, an integer less than or equal to 80, an integer less than or equal to 40, or an integer less than or equal to 20.

[0110] Here, “x+y+w”, representing the total number of monomers (Ia) and (Ib), monomers (II-a) and (II-b), and monomers (Ic) and (II-c), is preferably an integer that is 95% or more of z, each independently.

[0111] In addition, the “zxyw” of the total number of monomers (Id) and monomers (II-d) in each polymer represented by formulas (I) and (II) are each independently represented as an integer and are optionally 0.

[0112] For monomers (III-a) and (IV-a), x is preferably an integer that is more than 50% of z, each independently.

[0113] In addition, the “zx” in each polymer represented by formulas (III) and (IV) represents an integer, and is optionally 0.

[0114] B represents C 1-20 Halogenated alkyl groups.

[0115] The "C" 1-20 "Halogenated alkyl" refers to a straight-chain or branched alkyl group with 1 to 20 carbon atoms in which one or more hydrogen atoms are replaced by halogen atoms, as indicated by "C". 1-20"Haloalkyl", for example, bromomethyl, 2-bromoethyl, 3-bromopropyl, 4-bromobutyl, 5-bromopentyl, 6-bromohexyl, iodomethyl, 2-iodoethyl, 3-iodopropyl, 4-iodobutyl, 5-iodopentyl, 6-iodohexyl, fluoromethyl, 2-fluoroethyl, 3-fluoropropyl, 4-fluorobutyl, 5-fluoropentyl, 6-fluorohexyl, tribromomethyl, trichloromethyl, trifluoromethyl, difluoromethyl, perfluoroethyl, perfluoropropyl, perfluoroisopropyl, perfluorobutyl, perfluoroisobutyl, perfluoro-sec-butyl, perfluoro - tert-butyl, perfluoropentyl, perfluorohexyl, perfluoroisohexyl, perfluoro-1,1-dimethylbutyl, perbromo-2,2-dimethylbutyl, periodo-3,3-dimethylbutyl, perfluoro-2-ethylbutyl, perfluoroheptyl, perfluorooctyl, perfluoro-3-methyloctyl, perfluorononyl, perfluorodecyl, perfluoroundecyl, perfluorododecyl, perbromotridecyl, perfluorotetradecyl, periodopentadecanyl, perfluorohexadecyl, perfluoroheptadecyl, perfluorooctadecanyl, perfluorononadecanyl, perfluoroeicosyl, etc.

[0116] The above "C" 1-20 "Haloalkyl" can have more than one oxygen atom forming an ether bond as a constituent atom of its carbon chain at insertable positions. As such a "C" 1-20 Haloalkyl (also written as "C") 1-20 Preferred specific examples of "haloalkoxyalkyl" include CF3OCF2-, CF3CF2OCF2-, (CF3)2CFOCF2-, CF3OCF2CF2-, CF3CF2OCF2CF2-, CF3OCF2CF2OCF2-, CF3CF2OCF2CF2OCF2-, CF3CF2OCF2CF2OCF2-, CF3CF2OCF2CF2OCF2CH2-, CF3CF2CF2OCF(CF3)-, and CF3CF2CF2OCF(CF3)CF2OCF(CF3)-.

[0117] Here, as "C" 1-20 "Haloalkyl", preferably a C-type compound in which one or more hydrogen atoms are replaced by fluorine atoms. 1-20 Alkyl groups, more preferably C groups in which all hydrogen atoms are replaced by fluorine atoms. 1-20 alkyl.

[0118] As mentioned above, D represents a group containing a cation, a group containing an anion, or a group represented by formula (VII).

[0119]

[0120] (In the formula, t represents an integer from 0 to 5,

[0121] ** indicates the bonding position with the -(CH2)q- group, and

[0122] G represents O or NH.

[0123] Here, D, representing a "cationic group," refers to any suitable group containing a cation, such as a group containing an ammonium cation. The structural unit (monomers (Ib) and (II-b)) having a cationic group is not essential in the polymers of the present invention, but by including such a monomer, a polycationic segment is formed within the haloalkylated segment, allowing the polymers of the present invention to more effectively form complexes with biopolymers used as pharmaceuticals (e.g., siRNA) under physiological conditions. Specifically, groups consisting of amino groups, amidine groups, and groups derived from diethylenetriamine selected from the group group shown in (i) to (iv) below can be cited as suitable "cationic groups."

[0124] (i)-J-(CH2) l1 -(NH-(CH2) m1 -) n1 -NH2

[0125] (ii)-J-(CH2) l2 -N(-(CH2) m2 -NH2)2

[0126] (iii)-J-(CH2) l3 -N((-(CH2) m3 -NH2)(-(CH2) m4 -NH-) n2 -H)

[0127] (iv)-J-(CH2) l4 -N(-(CH2) m5 -N(-(CH2) m6 -NH2)2)2

[0128] (In the formula, J represents NH or CONH, l1~l4 and m1~m6 are each preferably integers of 2 or 3, more preferably 2.)

[0129] n1 and n2 are each preferably independent integers from 1 to 3.

[0130] Here, the group shown in formula (i) can be cited as a more preferred "cationic group".

[0131] The structural units (monomers (Ib) and (II-b)) having the aforementioned "cationically-containing groups" may have thiol groups (-SH groups) at the ends of their side chains, i.e., at the ends of the aforementioned cationically-containing groups. These thiol groups react with each other, thereby forming a cross-linking reaction based on disulfide bonds. As a result, the polymers of the present invention exhibit increased associativity, yielding polymers capable of forming highly stable micelles. Furthermore, disulfide bonds are bonds that readily break under reducing conditions. Therefore, stable micelles can be maintained under non-reducing conditions, i.e., extracellularly, while under reducing conditions, i.e., intracellularly, inclusions can be released efficiently.

[0132] Therefore, in one embodiment, D is -NH + =C(=NH)-(CH2) o -SH, where o is an integer from 1 to 10, preferably an integer from 2 to 4.

[0133] Furthermore, "anionic group" as indicated by D refers to any suitable group containing an anion, such as a carboxyl group. For structural units having anionic groups, monomers (Ib) and (II-b) are not essential in the polymers of the present invention, but by including such monomers, thereby forming polyanionic segments within the haloalkylated segments, the polymers of the present invention can more effectively form complexes with biopolymers used as pharmaceuticals (e.g., platinum complex anticancer agents such as cisplatin and DACH-platin) under physiological conditions. Specifically, a carboxyl group can be cited as a suitable "anionic group".

[0134] Furthermore, monomers (Ib) and (II-b) having the group represented by D in "formula (VII)" are not essential in the polymers of the present invention, but by including such monomers, thereby forming polyanionic segments within the haloalkylated segments, the polymers of the present invention can more effectively form complexes with biopolymers used as pharmaceuticals (e.g., paclitaxel, etc.) under physiological conditions.

[0135] The NHCOR, NHCOOR, CONHR, or COOR groups represented by E are segments formed by converting the ends of the NH2 group (represented by D) which contains a cationic group, or the COOH group (represented by D) which contains anionic groups.

[0136] Specifically, if (i) above is transformed, it becomes (i') below. The same applies to other groups.

[0137] (i')-J-(CH2) l1 -(NH-(CH2) m1 -) n1 -NHCOR

[0138] Here, R represents an alkyl group having 3 to 20 carbon atoms or a group derived from lipids. For "alkyl group having 3 to 20 carbon atoms," refer to the section on "C..." 1-20 "Halogenated alkyl" refers to the alkyl group described above. Examples of "liquid-derived groups" include those obtained by removing hydrogen atoms from the OH groups of tocopherol and cholesterol.

[0139] In the polymers shown in formulas (I) and (II), the monomers (Ic) and (II-c) of the "haloalkylated segments" are each independently derived from any amino acid. Therefore, R 3 This indicates "any amino acid side chain" selected as monomer (Ic) and (II-c).

[0140] For example, as monomers (Ic) and (II-c), each can independently be any suitable cationic amino acid having a cationic group (e.g., amino, guanidinyl, imidazole, etc.) on its side chain. Examples include basic amino acids such as lysine, arginine, histidine, and ornithine. Alternatively, to improve the hydrophobicity of the cationic polyamino acid segment, it can contain both hydrophobic amino acids (e.g., leucine, isoleucine, valine, phenylalanine, proline, etc.) and cationic amino acids. Therefore, as R... 3 The side chains of the amino acids can be cited as suitable examples.

[0141] L 2 Indicates a single bond or L 3 L 3 The connector shown in expression (V) or (VI).

[0142]

[0143] (In the formula, m and n each independently represent integers from 0 to 5,

[0144] The asterisk (*) on the left indicates the bonding position with the -NH- group, and

[0145] The asterisk (*) on the right indicates the bonding position with the carbonyl group.

[0146] In the polymers shown in formulas (III) and (IV), (i)A represents a single bond, and (ii)m represents an integer from 0 to 2.

[0147] p, q, and r each independently represent integers from 1 to 10. s represents integers from 0 to 10.

[0148] (2) Hydrophilic polymer chain segment

[0149] In the polymers shown in formulas (I) to (IV), A represents a single bond or a hydrophilic polymer chain. When A represents a hydrophilic polymer chain, it is equivalent to a "hydrophilic polymer chain segment".

[0150] The aforementioned hydrophilic polymer chain can be composed of any suitable hydrophilic polymer. Examples of such hydrophilic polymers include poly(ethylene glycol), polysaccharides, poly(vinylpyrrolidone), poly(vinyl alcohol), poly(acrylamide), poly(acrylic acid), poly(methacrylamide), poly(methacrylic acid), poly(methacrylate), poly(acrylate), polyamino acids, poly(malic acid), poly(oxazoline), or derivatives thereof. Specific examples of polysaccharides include starch, dextran, fructan, and galactan. The polyethylene glycol can be, for example, polyethylene glycol with terminal modifications such as C1-C6 alkyl groups. Furthermore, for bonding with cationic polyamino acid segments or linking groups (also called "linkers"), commercially available polyethylene glycols with various terminal functional groups are readily available, and branched polyethylene glycols of various molecular weights are also readily available, therefore their use is preferred.

[0151] For the weight-average molecular weight of the above-mentioned hydrophilic polymer segments, relative to segment 1, it is preferably 10,000 to 80,000, more preferably 10,000 to 60,000, for example, it can be set to 10,000 to 40,000.

[0152] (3) Other polymer components

[0153] L in each polymer shown in formulas (I) to (IV) 1a and L 1b Each can independently represent a single bond or a linking group.

[0154] L 1a and L 1b When referring to a "linking group," it is the linking portion between the "haloalkylated segment" and the "hydrophilic polymer segment" in the polymer of the present invention.

[0155] Specifically, as L 1a The linking groups shown can be selected from -NH-, -O-, -O-L4-NH-, -CO-, -CH2-, and -O-L5-S-L6-NH- (where L4 to L6 each independently represent C). 1-6 Alkylene. The linking group in the group shown.

[0156] On the other hand, as L 1b The linking groups shown can be selected from -OCO-L7-CO-, -NH- and -NHCO-L8-CO- (where L7 and L8 each independently represent C).1-6 Alkylene. ) is the linking group in the group shown.

[0157] Here, as "C" 1-6 Alkylenes, for example, include -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -CH(CH3)-, -C(CH3)2-, -CH(C2H5)-, -CH(C3H7)-, -CH(CH(CH3)2)-, -(CH(CH3))2-, -CH2-CH(CH3)-, -CH(CH3)-CH2-, -CH2-CH2-C(CH3)2-, -C(CH3)2-CH2-CH2-, -CH2-CH2-CH2-C(CH3)2-, -C(CH3)2-CH2-CH2-CH2-.

[0158] The above, as a particularly preferred linking group, is L 1a -CO- can be cited as an example of L. 1b Examples include -NH-.

[0159] R in each polymer shown in formulas (I) to (IV) 1 and R 2 The term "optionally replaced C" indicates that the C is not explicitly replaced. 1-12 The "C" in "alkyl" 1-12 "Alkyl" refers to a straight-chain or branched alkyl group having 1 to 12 carbon atoms. Specific examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, 3-methyloctyl, nonyl, decyl, undecyl, dodecyl, etc.

[0160] The above "C" 1-12 The alkyl group is optionally substituted at substituted positions by 1 to 8 (preferably 1 to 5) substituents. Examples of such substituents include azide, alkynyl (e.g., ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 4-methyl-2-pentynyl, etc.), thiol, maleimide, acetalformyl, cyano, formyl, carboxyl, amino, (C 1-6 )alkoxycarbonyl, (C 2-7 Acylamide group, silyloxy group, silylamino group, and trialkylsiloxy group (alkylsiloxy groups are each independently composed of 1 to 6 carbon atoms), etc.

[0161] R 1 In the case where the substituent is, for example, formyl, carboxyl, or amino, the target binding site binds to C via these substituents. 1-12 Alkyl bonding.

[0162] Here, the targeted binding site is a site that specifically binds to substances derived from organisms and viruses, thereby forming a biological binding pair with the substance and possessing biological recognition function. Examples include antibodies or their fragments, or proteins, peptides, nucleic acid aptamers, sugars such as lactose, physiologically active substances such as folic acid, and sugars such as lactose and glucose, which have other functional or targeted properties.

[0163] As the aforementioned target binding site, for example, a peptide with a weight-average molecular weight of 50 to 20,000 is preferred, a peptide with a weight-average molecular weight of 100 to 10,000 is more preferred, and a peptide with a weight-average molecular weight of 150 to 3,000 is even more preferred.

[0164] Furthermore, the aforementioned peptide is preferably a peptide having 1 to 200 amino acid residues, more preferably a peptide having 1 to 100 amino acid residues, and even more preferably a peptide having 1 to 30 amino acid residues.

[0165] Examples of the aforementioned peptides include those capable of specifically binding to integrins involved in angiogenesis, intimal hypertrophy, and the proliferation of malignant tumors; specifically, RGD peptides are examples. Here, RGD peptide refers to a peptide containing the arginine-glycine-aspartic acid (RGD) sequence. Preferably, the RGD peptide can be a cyclic RGD (cRGD) peptide.

[0166] As described above, the polymer of the present invention, as one embodiment thereof, is used as R 1 The substituents in the polymer can bind to the target binding site, thus having the advantage of functioning as a drug carrier with a target binding site. Utilizing this feature, the polymer of the present invention can effectively deliver drugs to the target site.

[0167] In the polymers of the present invention, the structural units (monomers) constituting the above-mentioned "haloalkylated segments" may be the same or different. Taking monomer (Ia) as an example, the same monomer (Ia) (e.g., a monomer with p=1 (Ia-1(1))) may be polymerized, or two monomers (Ia) with different structures (e.g., a monomer with p=1 (Ia-1(1)) and a monomer with p=10 (Ia-1(2))) may be polymerized. Those skilled in the art may choose to implement the present invention appropriately according to their purpose.

[0168] Without limitation, as a preferred polymer of the present invention, polymers represented by formula (I) or (II) may be cited, wherein A represents a hydrophilic polymer chain and zxy or zxyw represents 0.

[0169] II. Manufacturing of the polymer of the present invention

[0170] The polymer of the present invention can be suitably manufactured using methods commonly known to those skilled in the art. It should be noted that while monomers and other raw materials used in the manufacture of the polymer of the present invention can be produced using methods known to them, commercially available products can also be used.

[0171] Specifically, it can be manufactured by appropriately combining the following processes:

[0172] i) A process of sequentially polymerizing a pre-prepared hydrophilic polymer chain with specified monomers (Ia)–(Ic), (II-a)–(II-c), (III-a), (III-b), (IV-a), or (IV-b) according to the target polymer structure, or

[0173] ii) The process of combining pre-polymerized haloalkylated segments with hydrophilic polymer segments, and the process of introducing other groups (e.g., haloalkyl) that constitute the polymer of the present invention.

[0174] More specifically, for example, the terminal amino group of a hydrophilic polymer (e.g., polyethylene glycol) with an amino group at the ω-terminus can be used as an initiator to sequentially polymerize an N-carboxylic anhydride (NCA) of a specified amino acid (monomer) with a protecting group introduced as needed. Then, a haloalkyl group can be introduced through deprotection or side-chain conversion to convert it into a haloalkylated segment. Alternatively, a polyamino acid with a protecting group introduced as needed can be synthesized first, and then combined with a hydrophilic polymer, followed by deprotection or side-chain conversion to synthesize a block copolymer with a haloalkylated segment. Various methods can be used to combine polyamino acids with hydrophilic polymers, a representative method being the pre-introduction of reactive functional groups at their respective ends and coupling. Examples include methods using condensing agents or active esterification to combine carboxyl and amino groups; methods using maleimide and thiols; and methods based on so-called click chemistry utilizing alkynes and azides.

[0175] The structural design and synthesis plan of the polymer of the present invention are suitable for those skilled in the art. For example, when the drug forming the complex is a "nucleic acid", the ratio of the number of amines (N) in the polymer to the number of phosphate groups (P) in the nucleic acid can be adjusted by adjusting the mixing ratio of the polymer to the nucleic acid. There are no limitations; for example, the N / P ratio can be designed to be in the range of 0.1 to 5.0.

[0176] III. Regarding the use of the polymer of the present invention as a drug carrier

[0177] (1) Polymer-drug complex

[0178] The polymers of this invention can form complexes (e.g., polyionic complexes (PICs)) through interaction with drugs. The polymers of this invention improve the stability of the polymer-drug complex through the effects of the "haloalkylated segments" (e.g., the effects of interactions between polyfluorinated compounds). This enables increased blood retention, thereby improving the clinical efficacy of the drug.

[0179] In addition, the polymers of the present invention can also form polymer-drug complexes by covalently bonding with pharmaceutical agents.

[0180] (2) Target drugs

[0181] The pharmaceuticals to which the polymers of the present invention are adapted are not particularly limited, but suitable examples include, for instance, anionic compounds that have more negative charge than positive charge in aqueous solvents at physiological pH (e.g., pH 7.4). From this viewpoint, biopolymers are preferred.

[0182] Here, biomolecules refer to macromolecules derived from living organisms and macromolecules with similar structures, specifically including proteins, lipids, and nucleic acids. Preferably, the aforementioned biomolecules are at least one selected from the group consisting of proteins and nucleic acids. Here, proteins include peptides.

[0183] The aforementioned nucleic acid refers to a polynucleotide or oligonucleotide whose basic unit is a nucleotide composed of a purine or pyrimidine base, a pentose sugar, and a phosphate group. Examples include oligodouble-stranded RNA or polydouble-stranded RNA, oligodouble-stranded DNA or polydouble-stranded DNA, oligosingle-stranded DNA or polysingle-stranded DNA, and oligosingle-stranded RNA or polysingle-stranded RNA. It also includes oligodouble-stranded nucleic acids or polydouble-stranded nucleic acids, oligosingle-stranded nucleic acids or polysingle-stranded nucleic acids in which RNA and DNA are mixed within the same strand. Furthermore, the nucleotides contained in the nucleic acid can be of the native type or of a chemically modified non-native type, and may also contain added amino groups, thiol groups, fluorescent compounds, etc. There are no limitations; the nucleic acid can be composed of 4 to 20,000 bases, preferably 10 to 10,000 bases, and more preferably 12 to 30 bases. In addition, considering function or role, examples include plasmid DNA, siRNA, microRNA, mRNA, shRNA, antisense nucleic acid, decoy nucleic acid, nucleic acid aptamers, and ribozymes.

[0184] Other suitable examples of pharmaceuticals to which the polymers of the present invention are applicable include platinum complex anticancer agents such as cisplatin and DACH-platin, which can form complexes by means of coordination bonds.

[0185] As another suitable example of a drug to which the polymer of the present invention is adapted, hydrophobic anticancer agents such as paclitaxel, which can form complexes by means of hydrophobic interactions, can be cited.

[0186] The pharmaceutical product to which this invention is applied may or may not contain a haloalkyl group. Those skilled in the art can suitably perform this chemical modification based on the structure of the target pharmaceutical product.

[0187] (3) Preparation of polymer-drug complexes

[0188] Polymer-drug complexes can be prepared by those skilled in the art using methods known to them. For example, they can be prepared by applying ultrasonic irradiation-based energy to a mixture of the polymer and drug of the present invention while stirring. Alternatively, the complex can be prepared, for example, by mixing the polymer and drug of the present invention in any buffered aqueous solution (e.g., Tris buffer, phosphate-buffered saline, HEPES buffer, etc.).

[0189] The size of the aforementioned composite can be set to any appropriate size depending on the purpose. For example, the average particle size obtained by dynamic scattering measurement (DLS) is preferably 5 nm to 200 nm, more preferably 10 nm to 100 nm.

[0190] (4) Pharmaceuticals containing polymer-drug complexes

[0191] The polymer-drug complex of the present invention can be administered to the recipient who needs to be administered a medicine (drug delivery formulation) in its own form or in the form of a pharmaceutical composition containing the complex as an active ingredient.

[0192] Preferred subjects for drug administration include mammals such as humans, dogs, cats, horses, cattle, and other mammals. Humans are particularly preferred as drug administration subjects.

[0193] In pharmaceutical formulation, in addition to the drug as the active ingredient, carriers or diluents and additives can be mixed to form a pharmaceutical composition. Depending on the needs, the pharmaceutical composition may contain other drugs used in combination.

[0194] As a dosage form, non-oral administration agents such as injections and intravenous drips are preferred.

[0195] Carriers or diluents can include aqueous solvents such as distilled water, sterile water, Ringer's solution, physiological saline, and buffer solutions.

[0196] As additives, examples that are permitted in pharmaceuticals include expanders, dispersants, buffers, preservatives, solubilizers, stabilizers, isotonic agents, and pH adjusters.

[0197] For example, intravenous administration, intra-arterial administration, and intracerebral administration are preferred routes of administration.

[0198] The content of the drug in the pharmaceutical composition and the method of administration (usage and dosage) can be appropriately determined by those skilled in the art based on the specific morphology of the polymer according to the present invention, the drug used, and other individual circumstances.

[0199] Taking the use of nucleic acids as a drug as an example, the dosage of the aforementioned nucleic acids, in human cases, is non-limiting, and per dose, converted to siRNA molecules or antisense nucleic acid molecules per kg of adult body weight, is, for example, approximately 0.0001 mg to approximately 1,000 mg. However, the dosage is usually selected considering the gender, age, weight, symptoms, severity of illness, side effects, etc., of the recipient. Furthermore, administration can be carried out at intervals of, for example, 1 week, 2 weeks, 3 weeks, or 4 weeks, or at intervals exceeding 1 month as needed. As for the route of administration, as described above, for example, intravenous administration, intra-arterial administration, intracerebral administration, etc., can be selected.

[0200] Example

[0201] The present invention will now be described in more detail through examples of manufacturing the polymer of the present invention, examples of preparing a complex with the drug, and examples of animal experiments for evaluating its efficacy. However, these do not limit the present invention, and variations may be made without departing from the scope of the present invention.

[0202] 1. Reagents, cells, laboratory animals, etc.

[0203] (1) Synthetic reagents

[0204] PEG-NH2 was purchased from Nippon Oil Co., Ltd. (product name: SUNBRIGHT MEPA-12T). Methanol, thiourea, N,N-dimethylformamide (DMF), calcium hydride, and triethylamine were purchased from FUJIFILM Wako Pure Chemical Corporation. DMF was purified by vacuum distillation in the presence of calcium hydride before use. N-carboxylic anhydride of ε-trifluoroacetyl-L-lysine was purchased from Central Chemical Products Co., Ltd. Diethyl ether was purchased from SHOWA-ETHER. Dialysis tubing was purchased from SPECTRUM. C7F 15 -COOCH3 (hereinafter also referred to as "Rf-A"; see the structural formula on the left below), C5F 11 O2COOCH3 (hereinafter also referred to as "Rf-B"; see the structural formula on the right below) uses commercially available products.

[0205]

[0206] Hereinafter, "haloalkyl" introduced into polymers or the like through the reaction with the above-mentioned Rf-A or Rf-B will sometimes be abbreviated as Rf group, and those derived from Rf-A will be abbreviated as Rf-1 group, and those derived from Rf-B will be abbreviated as Rf-2 group.

[0207] (2) Nucleic acid

[0208] Single-stranded antisense oligonucleotides (ASOs) and hybrid nucleic acids (HDOs) consisting of a double-stranded ASO and a complementary strand were used (purchased from GeneDesign). Both ASOs and HDOs targeted the mouse MALAT1 (metastasis associated in lungadenocarcinoma transcript-1) sequence.

[0209] (Nucleic acid sequence)

[0210] 1)ASO sequence: 5'-C(L)^T(L)^A(L)^g^t^t^c^a^c^t^g^a^a^T(L)^G(L)^C(L)-3'

[0211] 2) HDO

[0212] HDO sequence 1: ASO sequence (5'-C(L)^T(L)^A(L)^g^t^t^c^a^c^t^g^a^a^T(L)^G(L)^C(L)-3')

[0213] HDO sequence 2: complementary sequence (5'-G(M)^C(M)^A(M)^UUCAGUGAAC^U(M)^A(M)^G(M)-3')

[0214] In the above formula,

[0215] a) The designation “N(L)” indicates cross-linked nucleic acid (LNA). Specifically, C(L) represents LNA 5-methylcytosine, T(L) represents LNA thymine, A(L) represents LNA adenine, and G(L) represents LNA guanine.

[0216] b) Nucleotides recorded in lowercase letters represent DNA.

[0217] c) Nucleotides recorded in uppercase letters represent RNA, and N(M) represents 2'-O-methyl RNA.

[0218] d)^ indicates thiophosphate modification.

[0219] (Nucleic acid manufacturing)

[0220] For HDO, HDO sequence 1 and HDO sequence 2 are annealed and used.

[0221] The Rf-1 base is introduced into the HDO at the end of the sequence using known methods.

[0222] (3) Animals

[0223] BALB / c mice (female, 6 weeks old) were used.

[0224] 2. Synthesis of polyethylene glycol-poly(L-lysine) block copolymer (PEG-PLys(Rf)) with Rf groups Book Manufacturing of the invented polymer )

[0225] (1) 300 mg of PEG-NH2 with an average molecular weight of 12,000 and 456 mg of thiourea were dissolved in 6 mL of N,N-dimethylformamide (DMF). The resulting solution was then added to a solution obtained by dissolving 310 mg of N-carboxylic anhydride of ε-trifluoroacetyl-L-lysine (Lys(TFA)-NCA)) and 456 mg of thiourea in 6 mL of DMF, and the reaction was carried out at 25 °C for 3 days. The reaction solution was added dropwise to 200 mL of a mixed solvent of diethyl ether / methanol (v / v: 15 / 1), resulting in a white precipitate. The precipitate was then dissolved in methanol and added dropwise to 200 mL of diethyl ether, and this operation was repeated twice. The resulting white precipitate was filtered and dried under vacuum to obtain PEG-PLys(TFA).

[0226] 200 mg of the obtained PEG-PLys (TFA) was dissolved in 18 mL of methanol, and 2 mL of 1 M sodium hydroxide solution was added. The reaction was carried out at 35 °C for 24 hours. The reaction solution was placed in a dialysis tube (molecular weight cutoff 6,000-8,000 Da), and dialysis was performed 4 times with 0.01 M NaOH solution as the external solution and 3 times with pure water as the external solution. The fluid inside the dialysis membrane was recovered and freeze-dried to obtain PEG-PLys as a white powder. 1 The obtained compound was confirmed by H-NMR to be the target compound, with a Plys degree of polymerization of 40. The structure is described below.

[0227]

[0228] (2) Dissolve 20 mg of PEG-Plys in 2 mL of methanol and 1.2 equivalents of triethylamine relative to the primary amino group of PEG-Plys. Add 0.1, 0.3, and 0.5 equivalents of Rf-A or Rf-B relative to the primary amino group of PEG-Plys, respectively, and stir overnight to carry out the reaction.

[0229] Each reaction solution was placed in a dialysis tube and dialyzed twice with methanol (each for more than 12 hours), three times with 10 mM phosphate buffer (pH 7.4) (each for more than 2 hours), three times with 100 mM NaCl aqueous solution (each for more than 2 hours), and three times with pure water (each for more than 2 hours). After lyophilization, PEG-PLys (Rf-AX) and PEG-PLys (Rf-BX) were obtained as white powders (X corresponds to 0.1, 0.3, and 0.5 of the input amount, respectively).

[0230] 3. Preparation of polymer-drug complex particles based on a mixture of nucleic acids and PEG-PLys(Rf)

[0231] The ASO, HDO, and Rf-1-HDO (hereinafter sometimes simply referred to as "Rf-HDO") were prepared using 10 mM HEPES (pH 7.3) to achieve concentrations of 80 μM, 40 μM, and 40 μM, respectively. PEG-PLys (control polymer), PEG-PLys (Rf-A0.3) (the polymer of the present invention), and PEG-PLys (Rf-B0.5) (the polymer of the present invention) were prepared using 10 mM HEPES (pH 7.3) to achieve a concentration of 1 mg / mL. The solutions were mixed at the following mixing ratio (volume ratio) and stirred by vortexing for 1 minute to prepare particles.

[0232] (Preparation of Particle 1)

[0233] Complex with PEG-PLys (N / P ratio = 1.4)

[0234] Nucleic acid / PEG-PLys / HEPES=60 / 47 / 133

[0235] (Preparation of Particle 2)

[0236] The complex with PEG-PLys(Rf-A0.3) (N / P ratio = 1.2)

[0237] Nucleic acid / PEG-PLys(Rf-A0.3) / HEPES = 60 / 71 / 109

[0238] (Preparation of Particle 3)

[0239] The complex with PEG-PLys(Rf-B0.5) (N / P ratio = 1.4)

[0240] Nucleic acid / PEG-PLys(Rf-B0.5) / HEPES = 60 / 123 / 57

[0241] *) N / P ratio: The ratio when the number of primary amines in the polymer is set to [N] and the number of phosphate groups in the nucleic acid is set to [P] (=the ratio of positive charge to negative charge)

[0242] 4. Animal experiments (blood retention)

[0243] (1) Particles provided for the experiment

[0244] Using Alexa Fluoro 647 to identify ASO and HDO (identified by conventional methods), nucleic acid monomers and complex particles prepared under the conditions described in section 3 above were used for evaluation in animal experiments.

[0245] 1) Using ASO as nucleic acid particles (ASO series)

[0246] Test particle A: Labeled ASO monomer (used as control 1) (200 μL of 20 μM solution was administered) Figure 1 (Recorded as "Naked ASO")

[0247] Test particle B: Polymer-ASO composite prepared under the conditions described in 3. (Preparation of particle 1) above (used as control 2) Figure 1 (Recorded as "ASOxLys")

[0248] Experimental particle 1: Polymer-ASO composite prepared under the conditions described in 3. (Preparation of particle 2) above. Figure 1 (Recorded as "ASOxRf-1")

[0249] Experimental particle 2: Polymer-ASO composite prepared under the conditions described in 3. (Preparation of particle 3) above. Figure 1 (Recorded as "ASOxRf-2")

[0250] 2) Using HDO as nucleic acid particles (HDO series)

[0251] Test particle C: Labelled HDO monomer (used as control 1) (administer 200 μL of 10 μM solution) Figure 2 (Recorded as "Naked HDO")

[0252] Test particle D: Polymer-HDO composite prepared under the conditions described in 3. (Preparation of particle 1) above (used as control 2) Figure 2 (Recorded as "HDOxLys")

[0253] Experimental particle 3: Polymer-HDO composite prepared under the conditions described in 3. (Preparation of particle 2) above. Figure 2 (Recorded as "HDOxRf-1")

[0254] Experimental particle 4: Polymer-HDO composite prepared under the conditions described in 3. (Preparation of particle 3) above. Figure 2 (Recorded as "HDOxRf-2")

[0255] 3) Using Rf-1-modified HDO as nucleic acid particles (Rf-HDO series)

[0256] Test particle E: Identified Rf-1-HDO monomer (used as control 1) Figure 3 (Recorded as "Naked Rf-HDO")

[0257] Test particle F: Polymer-Rf-1-HDO composite prepared under the conditions described in 3. (Preparation of particle 1) above (used as control 2) Figure 3 (Recorded as "Rf-HDOxLys")

[0258] Experimental particle 5: Polymer-Rf-1-HDO composite prepared under the conditions described in 3. (Preparation of particle 2) above. Figure 3 (Recorded as "Rf-HDOxRf-1")

[0259] Experimental particle 6: Polymer-Rf-1-HDO composite prepared under the conditions described in 3. (Preparation of particle 3) above. Figure 3 (Recorded as "Rf-HDOxRf-2")

[0260] (2) Evaluation of blood retention

[0261] Each of the above-mentioned test particles was administered in 200 μL via the tail vein of mice. Blood samples were collected from the tail vein at 10, 30, 60, and 180 minutes after administration. The fluorescence intensity in the blood was measured using a fluorescence microplate reader (Tecan Spark), and the residual amount in the blood (Dose% / g) was quantified.

[0262] (3) Evaluation Results

[0263] The evaluation results will be presented later. Figures 1-3 .

[0264] Figure 1 The evaluation results are shown when ASO is used as the nucleic acid.

[0265] Figure 2 The evaluation results are shown when HDO is used as the nucleic acid.

[0266] Figure 3 The evaluation results are shown when HDO modified with Rf-1 group is used as nucleic acid.

[0267] In each graph, the horizontal axis represents the time after drug administration, and the vertical axis represents the blood concentration (Dose% / g).

[0268] Based on the above evaluation results, it is clear that by preparing a complex with the haloalkylated polymer of the present invention, the blood retention of nucleic acids is significantly improved. Figures 1-2 Furthermore, it was clarified that the same improved effect was obtained even when using halogenated nucleic acids to prepare complexes with the halogenated polymers of the present invention. Figure 3 ).

[0269] Industrial availability

[0270] The present invention provides polymers useful as carriers for effectively delivering drugs such as nucleic acid pharmaceuticals to target sites, for example, in the field of the pharmaceutical industry.

[0271] This application is based on Japanese Patent Application No. 2021-038762 (application date: March 10, 2021), the contents of which are contained in this specification.

Claims

1. A polymer represented by the following formula (I), (II), (III) or (IV), In equation (I), R 1 Represents a hydrogen atom or an optional substituted C atom 1-12 Alkyl, R 2 Indicates that C is arbitrarily replaced. 1-12 Alkyl; in formula (II), (III) or (IV), R 1 and R 2 Each can independently represent a hydrogen atom or an optional substituted C atom. 1-12 alkyl; In formulas (I), (II), (III), or (IV), R 3 Represents the side chain of any amino acid. A represents a single bond or a hydrophilic polymer chain. L 1a and L 1b Each can independently represent a single bond or a linking group. L 2 Indicates a single bond or L 3 , L 3 The connector shown in expression (V) or (VI) In the formula, m and n each independently represent integers from 0 to 5. The asterisk (*) on the left indicates the bonding position with the -NH- group, and The asterisk (*) on the right indicates the bonding position with the carbonyl group. B represents C where all hydrogen atoms are replaced by fluorine atoms, and where there is one or more oxygen atoms forming ether bonds at insertable positions as constituent atoms of its carbon chain. 1-20 Fluoroalkyl, D represents a group containing a cation, a group containing an anion, or a group represented by formula (VII). In the formula, t represents an integer from 0 to 5. ** indicates the bonding position with the -(CH2)q- group, and G represents O or NH. E represents NHCOR group, NHCOOR group, CONHR group, or COOR group. R represents an alkyl group with 3 to 20 carbon atoms or a lipid-derived group. z represents an integer from 2 to 500. x represents the integers greater than 40% of z. y represents an integer, which can be arbitrarily set to 0. w represents an integer, which can be arbitrarily set to 0. zxyw represents an integer, which can be arbitrarily set to 0. zx represents an integer, which can be arbitrarily set to 0. p, q, and r each independently represent integers from 1 to 10. s represents an integer from 0 to 10. in, In equations (III) and (IV), (i)A represents a single bond, and (ii)m represents an integer from 0 to 2.

2. The polymer according to claim 1, wherein, In formula (I) or (II), the sum of x, y and w is more than 95% of z.

3. The polymer according to claim 1, wherein, A is a hydrophilic polymer chain.

4. The polymer according to claim 1, wherein, A represents a single bond.

5. A polymer-drug complex formed by combining the polymer of claim 1 with a drug.

6. The polymer-drug complex according to claim 5, wherein, Drugs are biological macromolecules.

7. A pharmaceutical product comprising the polymer-drug complex of claim 5 as an active ingredient.

Citation Information

Patent Citations

  • Particle composition and pharmaceutical composition using particle composition

    WO2012096399A1

  • Antitumor drug delivery formulation

    WO2017086467A1

  • Block copolymer having phenylboronic acid group introduced therein, and use thereof

    CN104093768A

  • Micelle composition for nucleic acid delivery using temperature-sensitive polymer and method for producing same

    US20180289835A1

  • Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds

    US6677164B1